For decades, cancer immunotherapy has promised to enlist the body's own defenses against malignancy, yet most patients still find themselves outmaneuvered by tumors that hide, adapt, and exhaust the immune cells sent to destroy them. Researchers at Nankai University have proposed a new way of thinking about this impasse: rather than engineering nanomaterials to solve one problem at a time, they argue for integrated platforms that simultaneously breach tumor barriers, restore immune recognition, and dismantle the suppressive environment within the tumor itself. Published in the spring of 2026,